Mativ Holdings, Inc.

DB:MH2 Stock Report

Market Cap: €598.3m

Mativ Holdings Valuation

Is MH2 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

6/6

Valuation Score 6/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of MH2 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: MH2 (€10.7) is trading below our estimate of fair value (€37.2)

Significantly Below Fair Value: MH2 is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for MH2?

Key metric: As MH2 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for MH2. This is calculated by dividing MH2's market cap by their current revenue.
What is MH2's PS Ratio?
PS Ratio0.3x
SalesUS$1.97b
Market CapUS$622.69m

Price to Sales Ratio vs Peers

How does MH2's PS Ratio compare to its peers?

The above table shows the PS ratio for MH2 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average1x
SIM0 SIMONA
0.6xn/a€342.0m
FPE3 Fuchs
1.6x3.7%€4.8b
IBU IBU-tec advanced materials
0.7x12.7%€32.4m
ACT AlzChem Group
1x7.2%€590.2m
MH2 Mativ Holdings
0.3x1.7%€622.7m

Price-To-Sales vs Peers: MH2 is good value based on its Price-To-Sales Ratio (0.3x) compared to the peer average (1x).

Price to Sales Ratio vs Industry

How does MH2's PS Ratio compare vs other companies in the European Chemicals Industry?

27 CompaniesPrice / SalesEstimated GrowthMarket Cap
MH2 0.3xIndustry Avg. 1.0xNo. of Companies30PS01.22.43.64.86+
27 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: MH2 is good value based on its Price-To-Sales Ratio (0.3x) compared to the European Chemicals industry average (1x).

Price to Sales Ratio vs Fair Ratio

What is MH2's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

MH2 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio0.3x
Fair PS Ratio0.3x

Price-To-Sales vs Fair Ratio: MH2 is good value based on its Price-To-Sales Ratio (0.3x) compared to the estimated Fair Price-To-Sales Ratio (0.3x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst MH2 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€10.70
€16.38
+53.1%
11.7%€19.08€14.79n/a3
Dec ’25€12.30
€16.38
+33.1%
11.7%€19.08€14.79n/a3
Nov ’25€13.90
€22.32
+60.6%
22.4%€27.34€17.31n/a2
Oct ’25€14.90
€22.32
+49.8%
22.4%€27.34€17.31n/a2
Sep ’25€17.00
€22.32
+31.3%
22.4%€27.34€17.31n/a2
Aug ’25€17.00
€22.71
+33.6%
22.4%€27.81€17.61n/a2
Jul ’25€14.70
€22.71
+54.5%
22.4%€27.81€17.61n/a2
Jun ’25€16.40
€22.71
+38.5%
22.4%€27.81€17.61n/a2
May ’25€16.90
€22.58
+33.6%
22.4%€27.65€17.51n/a2
Apr ’25€17.10
€22.58
+32.0%
22.4%€27.65€17.51n/a2
Mar ’25€16.20
€22.58
+39.4%
22.4%€27.65€17.51n/a2
Feb ’25€10.70
€19.37
+81.1%
19.0%€23.07€15.68n/a2
Jan ’25€13.90
€19.38
+39.4%
19.0%€23.08€15.69n/a2
Dec ’24€10.60
€19.62
+85.1%
19.0%€23.36€15.88€12.302
Nov ’24€11.90
€26.03
+118.8%
5.3%€27.41€24.66€13.902
Oct ’24€13.40
€26.03
+94.3%
5.3%€27.41€24.66€14.902
Sep ’24€15.30
€26.03
+70.2%
5.3%€27.41€24.66€17.002
Aug ’24€16.20
€25.94
+60.1%
7.1%€27.79€24.08€17.002
Jul ’24€13.80
€25.94
+87.9%
7.1%€27.79€24.08€14.702
Jun ’24€13.70
€25.74
+87.9%
7.1%€27.58€23.90€16.402
May ’24€17.30
€31.72
+83.4%
2.9%€32.63€30.81€16.902
Apr ’24€19.50
€32.28
+65.6%
2.9%€33.21€31.36€17.102
Mar ’24€24.20
€33.08
+36.7%
2.9%€34.03€32.14€16.202
Feb ’24€24.60
€32.89
+33.7%
9.9%€36.14€29.65€10.702
Jan ’24€19.30
€34.65
+79.5%
12.3%€38.92€30.38€13.902

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 03:26
End of Day Share Price 2024/12/23 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Mativ Holdings, Inc. is covered by 11 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jonathan TanwantengCJS Securities, Inc.
Robert LabickCJS Securities, Inc.
Steven ChercoverD.A. Davidson & Co.